The mechanism of RTX-ILD remains unknown, however several studies have demonstrated rapid lymphocyte lysis, complement activation, and Tumor Necrosis Factor (TNF) alpha release that occur after rituximab infusion [13]. Here, TNF is linked to interstitial lung disease.